Skip to main content
NCBI home page
BMC Medicine logoLink to BMC Medicine
. 2022 Dec 8;20:478. doi: 10.1186/s12916-022-02695-5

Correction: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

Taku Kinoshita 1,2, Masahiro Shinoda 3, Yasuhiro Nishizaki 4, Katsuya Shiraki 5, Yuji Hirai 6, Yoshiko Kichikawa 7, Kenji Tsushima 1, Masaharu Shinkai 3, Naoyuki Komura 8, Kazuo Yoshida 9, Yasutoshi Kido 10,11,12, Hiroshi Kakeya 13,14, Naoto Uemura 15,✉, Junichi Kadota 16,17
PMCID: PMC9733017  PMID: 36482439

Correction: BMC Med 20, 342 (2022)

https://doi.org/10.1186/s12916-022-02518-7

The original article [1] contained a small typo in Masaharu Shinkai’s name which has since been corrected.

Reference

  • 1.Kinoshita T, et al. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study) BMC Med. 2022;20:342. doi: 10.1186/s12916-022-02518-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Medicine are provided here courtesy of BMC

RESOURCES